Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Semapimod. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FURIN | P09958 | 14/20 | 0.85 |
| ▸ | F10 | P00742 | 2/20 | 0.81 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.67 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.67 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.67 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.67 |
| ▸ | PRKCG | P05129 | 2/20 | 0.67 |
| ▸ | CDK1 | P06493 | 2/20 | 0.67 |
| ▸ | PIM1 | P11309 | 2/20 | 0.67 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.67 |
| ▸ | CDK2 | P24941 | 2/20 | 0.67 |
| ▸ | AKT1 | P31749 | 2/20 | 0.67 |
| ▸ | AKT2 | P31751 | 2/20 | 0.67 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.67 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.67 |
| ▸ | NEK2 | P51955 | 2/20 | 0.67 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.67 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.67 |
| ▸ | PRKCZ | Q05513 | 2/20 | 0.67 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Semapimod SCHEMBL18758868 | 1.00 | FURIN (0.85) | FURINF10CHEK1DAPK3ROCK2 | |
| Semapimod SCHEMBL29624033 | 0.99 | FURIN (0.83) | FURINF10CHEK1DAPK3ROCK2 | |
| Semapimod SCHEMBL1649211 | 0.97 | FURIN (0.81) | FURINF10CHEK1DAPK3ROCK2 | |
| SCHEMBL11989635 | 0.80 | PLK4 (0.63) | FURINF10CHEK1DAPK3ROCK2 | |
| Semapimod SCHEMBL6150586 | 0.80 | PLK4 (0.63) | FURINF10CHEK1DAPK3ROCK2 | |
| Semapimod SCHEMBL12201344 | 0.80 | PLK4 (0.63) | FURINF10CHEK1DAPK3ROCK2 | |
| SCHEMBL6149232 | 0.79 | FURIN (0.56) | FURINF10MEN1KMT2APARP1 | |
| SCHEMBL8445590 | 0.79 | FURIN (0.56) | FURINF10MEN1KMT2APARP1 | |
| SCHEMBL5442050 | 0.79 | FURIN (0.56) | FURINF10MEN1KMT2APARP1 | |
| SCHEMBL8446705 | 0.79 | FURIN (0.56) | FURINF10MEN1KMT2APARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 316 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260053790-A1 | TREATMENTS FOR CONDITIONS INVOLVING INCREASED IL-6 LEVELS | X4 PHARMACEUTICALS INC (US) | 2026-02-26 | — | — | US | claimed |
| WO-2023240259-A1 | TREATMENTS FOR CONDITIONS INVOLVING INCREASED IL-6 LEVELS | X4 PHARMACEUTICALS, INC. (US) | 2023-12-14 | — | — | WO | claimed |
| US-20230287098-A1 | POLYPEPTIDES | VHSQUARED LIMITED (GB) | 2023-09-14 | — | — | US | claimed |
| WO-2023133409-A2 | COMBINATION THERAPIES INCLUDING PARP1 INHIBITORS | CORNELL UNIVERSITY (US) | 2023-07-13 | — | — | WO | claimed |
| US-20230157994-A1 | NEW COMPOSITIONS AND METHODS OF TREATING COVID-19 DISEASE | 4LIVING BIOTECH (FR) | 2023-05-25 | — | — | US | claimed |
| CN-116133657-A | New compositions and methods for treating covd-19 disease | 4活性生物科技公司 | 2023-05-16 | — | — | CN | claimed |
| CN-107454905-B | Polypeptides | 索里索制药公司 | 2023-04-28 | — | — | CN | claimed |
| EP-4146195-A1 | NEW COMPOSITIONS AND METHODS OF TREATING COVID-19 DISEASE | 4Living Biotech (FR) | 2023-03-15 | — | — | EP | claimed |
| EP-4126002-A1 | METHODS OF TREATING PULMONARY INJURY WITH CGRP INHIBITORS | Biohaven Pharmaceutical Holding Company Ltd. (US) | 2023-02-08 | — | — | EP | claimed |
| EP-3277719-B1 | POLYPEPTIDES | SORRISO PHARMACEUTICALS INC (US) | 2022-03-16 | — | — | EP | claimed |
| US-20260144674-A1 | Apparatus and Methods for Drug Delivery Using Microneedles | CLEARSIDE BIOMEDICAL, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| EP-3523331-B1 | CHIMERIC ANTIGEN RECEPTORS FOR THE TREATMENT OF CANCER | NOVARTIS AG (CH) | 2026-05-27 | — | — | EP | disclosed |
| US-12624118-B2 | Trispecific binding molecules against BCMA and uses thereof | NOVARTIS AG (CH) | 2026-05-12 | — | — | US | disclosed |
| US-20260109774-A1 | CHIMERIC ANTIGEN RECEPTORS SPECIFIC FOR B-CELL MATURATION ANTIGEN AND ENCODING POLYNUCLEOTIDES | JUNO THERAPEUTICS, INC. (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4725503-A2 | CHIMERIC ANTIGEN RECEPTORS TARGETING CANCER | University Of Southern California (US) | 2026-04-15 | — | — | EP | disclosed |
| CN-114173810-A | Trispecific binding molecules directed against BCMA and uses thereof | 诺华股份有限公司 | 2022-03-11 | — | — | CN | disclosed |
| CN-114126649-A | anti-T cell antigen binding molecules for use in combination with cytokine inhibitors | 中外制药株式会社 | 2022-03-01 | — | — | CN | disclosed |
| CN-110177527-B | Device and method for adjusting insertion depth of needle for medicament delivery | 科尼尔赛德生物医学公司 | 2022-02-01 | — | — | CN | disclosed |
| CN-114008039-A | N- (5- (6-ethoxypyrazin-2-yl) pyridin-2-yl) -4- (2- (methylsulfonylamino) pyrimidin-4-yl) tetrahydro-2H-pyran-4-carboxamide derivatives and related compounds as human CTPS1 inhibitors for the treatment of proliferative diseases | 斯泰普制药股份公司 | 2022-02-01 | — | — | CN | disclosed |
| WO-2012010641-A2 | PHARMACEUTICAL COMPOSITION FOR INCREASING CELLULAR HYPOXIC TOLERANCE | UNIVERSITE DE NICE SOPHIA ANTIPOLIS (FR) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109774-A1 | CHIMERIC ANTIGEN RECEPTORS SPECIFIC FOR B-CELL MATURATION ANTIGEN AND ENCODING POLYNUCLEOTIDES | CD2BP2, CD22, FCGR2A | FURIN 3995/4885F10 3937/4885CHEK1 2479/4885 |
| US-20260144674-A1 | Apparatus and Methods for Drug Delivery Using Microneedles | PROKR2, SLC10A2, GLP1R | FURIN 37/4885F10 1199/4885CHEK1 4721/4885 |
| US-12624118-B2 | Trispecific binding molecules against BCMA and uses thereof | CD2, CD40, CD22 | FURIN 4326/4885F10 3397/4885CHEK1 2303/4885 |
| US-20260053790-A1 | TREATMENTS FOR CONDITIONS INVOLVING INCREASED IL-6 LEVELS | CXCR6, IL6, CCR6 | FURIN 2554/4885F10 1348/4885CHEK1 2402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.